Glenmark Life Sciences Ltd
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.[1]
- Market Cap ₹ 10,455 Cr.
- Current Price ₹ 853
- High / Low ₹ 972 / 596
- Stock P/E 29.7
- Book Value ₹
- Dividend Yield 2.64 %
- ROCE %
- ROE %
- Face Value ₹ 2.00
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | |
---|---|---|---|
886 | 1,537 | 1,885 | |
639 | 1,065 | 1,294 | |
Operating Profit | 248 | 472 | 591 |
OPM % | 28% | 31% | 31% |
0 | 12 | 1 | |
Interest | 1 | 34 | 88 |
Depreciation | 19 | 29 | 33 |
Profit before tax | 228 | 421 | 471 |
Tax % | 14% | 26% | 25% |
196 | 313 | 352 | |
EPS in Rs | 997.86 | 1,597.37 | 358.74 |
Dividend Payout % | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 12% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 34% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | |
---|---|---|---|
Equity Capital | |||
Reserves | |||
Total Liabilities | |||
CWIP | |||
Investments | |||
Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | |
---|---|---|---|
Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | |
---|---|---|---|
Debtor Days | |||
Inventory Days | |||
Days Payable | |||
Cash Conversion Cycle | |||
Working Capital Days | |||
ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
18 Jul - Details of Earnings Call slated for Friday, July 26, 2024 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record.
- Closure of Trading Window 18 Jul
- Board Meeting Intimation for Inter Alia, To Consider And Approve The Unaudited Financial Results Of The Company For The First Quarter Ended 30Th June, 2024. 18 Jul
- Intimation Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015 ('Listing Regulations') - Minimum Public Shareholding. 16 Jul
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 16 Jul
Annual reports
Concalls
-
May 2024Transcript PPT
-
Mar 2024TranscriptNotesPPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Jul 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
Apr 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
History
Prior to 2019 API business was an integral part of Glenmark Pharma (GPL). It was separated out of GPL into GLS through a Business Transfer Agreement in Jan 2019. GLS was listed on NSE & BSE in FY22. [1]